Products Gardasil
Gardasil Pre-clinical UNKNOWN 💤 Quiet Anal Cancer, HIV Infections
Jun 1, 2008 → Jun 1, 2012
About Gardasil Gardasil is a pre-clinical stage product being developed by Merck for Anal Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT00666107. Target conditions include Anal Cancer, HIV Infections.
Clinical Trials (8) NCT ID Phase Status Start Completion Indication NCT04022148 Pre-clinical UNKNOWN Aug 1, 2019 Dec 31, 2020 Cancer of Cervix NCT01432574 Phase 2 Completed Feb 19, 2013 Nov 3, 2020 Human Papillomavirus NCT01741012 Phase 1 Completed Jan 1, 2013 Nov 1, 2015 Systemic Lupus Erythematosus NCT01338051 Phase 1 Completed May 1, 2011 Apr 1, 2012 Cervical Intraepithelial Neoplasia NCT00925288 Approved Completed Oct 1, 2009 Aug 1, 2011 Human Papillomavirus Infection NCT01133509 Pre-clinical UNKNOWN Sep 1, 2009 Oct 1, 2012 Genital Human Papilloma Virus Infection NCT00786409 Pre-clinical Completed Nov 1, 2008 Dec 1, 2011 Systemic Lupus Erythematosus NCT00666107 Pre-clinical UNKNOWN Jun 1, 2008 Jun 1, 2012 Anal Cancer
Product Company Stage Hype Score aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib Johnson & Johnson Approved Acetaminophen Johnson & Johnson Phase 2 HRF2105 patch + Loxoprofen patch + placebo Jiangsu Hengrui Medicine Phase 2 Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation Jiangsu Hengrui Medicine Phase 1 Bupivacaine Liposome Injection Jiangsu Hengrui Medicine Approved Paracetamol injection + Normal Saline injection + Morhpine PCA Jiangsu Hengrui Medicine Phase 2/3 Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection Jiangsu Hengrui Medicine Phase 2 Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab AstraZeneca Phase 1 Org 28611 + morphine sulfate + Placebo Merck Phase 2 Pembrolizumab Merck Phase 2 Cetuximab + Mitomycin C + 5-Fluoruracil Merck Phase 1 Pembrolizumab + Paclitaxel + Carboplatin + Pembrolizumab Merck Phase 2 9-valent HPV vaccination Merck Phase 2 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Phase 2 Sample collection Novartis Phase 2 Atezolizumab plus Tiraglolumab Roche Phase 2 MPDL3280A + mDCF Roche Phase 2 panitumumab, mytomicin C, 5-FU, radiation Amgen Phase 2 oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride Pfizer Phase 1 Ibuprofen 600 mg Immediate Release/Extended Release Caplet Pfizer Phase 3
Other Products from Merck